2 research outputs found
Pharmacological evaluation of Prosopis ruscifolia extract on lipid profile in hyperglycemic and hyperlipidemic mice
La diabetes es una patología crónica grave, con efectos a largo plazo que incluyen daño a los vasos sanguíneos o dislipidemia diabética. La dislipidemia diabética se caracteriza por el aumento de las concentraciones de triglicéridos de baja densidad y lipoproteínas y una disminución de las lipoproteínas de alta densidad HDL-colesterol (HDL-c). Este estudio tuvo como objetivo evaluar el efecto de Prosopis ruscifolia sobre el perfil lipídico en ratones suizos albinos con hiperglucemia e hiperlipidemia.CONACYT – Consejo Nacional de Ciencia y TecnologíaPROCIENCI
Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases
Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease